Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants.: HP40-308/2022E-PDF
"The objective of this advisory committee statement is to review evidence and develop guidance on strategies to prevent severe consequences of Respiratory syncytial virus (RSV) infection in children at high risk of severe RSV disease by administration of monoclonal antibody"--Guidance objective, page 8.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.910768&sl=0
| Department/Agency |
|
|---|---|
| Title | Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Later edition | Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. |
| Format | Digital text |
| Electronic document | |
| Note(s) |
|
| Publishing information |
|
| Description | 1 online resource (151 pages) |
| ISBN | 9780660433523 |
| Catalogue number |
|
| Departmental catalogue number | 220087 |
| Subject terms |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.Page details
- Date modified: